Exicure Appoints Dr. Bali Muralidhar of Abingworth LLP and Bosun Hau of Tybourne Capital Management to its Board of Directors
August 07 2019 - 7:00AM
Business Wire
Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
constructs, today announced the appointment of Dr. Bali Muralidhar,
a partner at Abingworth LLP, and Mr. Bosun Hau, a managing director
and co-head of private equity at Tybourne Capital Management, to
its Board of Directors.
“We are excited to welcome two high caliber leaders like Dr.
Muralidhar and Mr. Hau to our board,” said Dr. Chad Mirkin, Ph.D.,
chairman of the board of Exicure. “Their insight and experience
will greatly benefit our strategic priorities and growth as we
advance our ongoing clinical programs and expand into new
therapeutic areas.”
Bali Muralidhar, M.D., Ph.D., has more than 15 years’ experience
in healthcare across a range of functions and currently serves as
partner at Abingworth LLP, an international investment group
dedicated to life sciences. Prior to joining Abingworth, Dr.
Muralidhar was a senior partner at MVM Partners LLP. Prior to MVM,
he was a member of Bain Capital’s leverage buyout team, focusing on
healthcare. He earned a degree in clinical medicine from the
University of Oxford and has a Ph.D. in translational cancer
research from the MRC Cancer Cell Unit, University of
Cambridge.
"Exicure has developed a new class of genetic medicines with a
differentiated platform for oligonucleotide drugs. The SNA
technology opens possibilities for DNA and RNA therapies in tissues
other than the liver. I am pleased to be joining the board during
this important time and to work with such a high-quality team,”
said Dr. Muralidhar. “Abingworth is delighted to have led Exicure’s
recent oversubscribed financing, which will help enable the company
to advance its rich pipeline of development candidates and bring
much needed therapies to unserved patients globally.”
Bosun Hau brings more than 15 years of life science experience
to Exicure’s board with a focus on emerging growth stage companies.
Previously, Mr. Hau served as managing director and partner at
Sailing Capital. He also served as a partner at MVM Partners and as
a consultant with McKinsey & Company. Prior to McKinsey, he was
part of GlaxoSmithKline’s corporate venture group and has also
served as an equity research analyst covering the medical device
and pharmaceutical industries for JP Morgan and Prudential. Mr. Hau
received a B.S. in Molecular and Cellular Biology, a B.S.H.S. in
Physiological Sciences and a B.A. in Psychology from the University
of Arizona, an M.Sc. in Biotechnology from Johns Hopkins University
and an M.B.A in Finance and Health Management from the Wharton
School at the University of Pennsylvania.
“I look forward to working with the Exicure board and management
team to bring additional strategic perspective to their pipeline
and advance innovative drug candidates from discovery through
development to benefit patients,” said Mr. Hau.
About Exicure, Inc. Exicure, Inc. is a clinical-stage
biotechnology company developing therapeutics for immuno-oncology,
inflammatory diseases and genetic disorders based on our
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure's lead program is in a Phase 1b/2 trial in
patients with advanced solid tumors. Exicure is based outside of
Chicago, IL and in Cambridge, MA. www.exicuretx.com
Forward Looking Statements This press release contains
forward-looking statements (including within the meaning of Section
21E of the United States Securities Exchange Act of 1934, as
amended, and Section 27A of the United States Securities Act of
1933, as amended) concerning the Company, the Company’s technology,
potential therapies, and other matters. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “expect,” “plan,”
“believe,” “intend,” “look forward,” and other similar expressions
among others. Statements that are not historical facts are
forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and
uncertainties and are not guarantees of future performance. Actual
results could differ materially from those contained in any
forward-looking statement as a result of various factors,
including, without limitation: unexpected costs, charges or
expenses that reduce cash runway; that Exicure’s pre-clinical or
clinical programs do not advance or result in approved products on
a timely or cost effective basis or at all; the cost, timing and
results of clinical trials; that many drug candidates that have
completed Phase 1 trials do not become approved drugs on a timely
or cost effective basis or at all; the ability to enroll patients
in clinical trials; possible safety and efficacy concerns;
regulatory developments; and the ability of Exicure to protect its
intellectual property rights. Risks facing the Company and its
programs are set forth in the Company’s filings with the SEC.
Except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190807005065/en/
MacDougall Karen Sharma 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024